== L I N E A G E The future of cell therapy. Corporate Overview April 25, 2022 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and there can be no assurance a ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Brian Culley – Chief Executive Officer Gary Hogge – SVP, Clinical and Medical Affairs Ioana Hone – Director of Investor Relations Conference Call Participants Joe Pantginis – H.C. Wainwright & Co., LLC Kristen Kluska – Cantor Fitzgerald Jason McCarthy – Maxim Group, LLC William Wood – B. Riley Securities Robert LeBoyer – Noble Capital Markets Operator Welcome to the Lineage Cell Therapeu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2021 Results Conference Call March 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head, IR Brian Culley - CEO Kevin Cook - CFO Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants Kristen Kluska - Cantor Fitzgerald Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Robert LeBoyer - Noble Capital Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2021 Conference Call. At this time, all parti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Call Start: 16:30 January 1, 0000 5:25 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 Earnings Conference Call November 10, 2021, 4:30 PM ET Company Participants Brian Culley – Chief Executive Officer Ioana Hone – Director of Investor Relations at Lineage Kevin Cook – Chief Financial Officer Gary Ho – Senior Vice President of Clinical and Medical Affairs Conference Call Participants William Buckley – B. Riley Joe Pantginis – H.C.W Rick or – Kantar Fitzgerald Michael Okunewitch – Maxim Group Dane Leone ...

Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 ( ...

The future of cell therapy. Corporate Overview September 15, 2021 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and there can be no assurance as to its accu ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Ioana Hone – Director of Investor Relations Brian Culley – Chief Executive Officer Kevin Cook – Chief Financial Officer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Joe Pantginis – H.C. Wainwright Dane Leone – RJF Operator Welcome to the Lineage Cell Therapeutics’ Second Quarter 2021 Conference Call. At this time, all participants are in a listen-only mode. An audio ...

Clinical Programs - Lineage is developing three clinical-stage allogeneic cell therapy programs: OpRegen for advanced dry age-related macular degeneration, OPC1 for subacute spinal cord injuries, and VAC2 for non-small cell lung cancer[154]. - OpRegen is currently in a Phase 1/2a clinical trial, targeting a condition that accounts for approximately 85-90% of all AMD cases, which is a leading cause of blindness in individuals over 60[154]. - OPC1's clinical trial is partially funded by the California Institute for Regenerative Medicine, focusing on spinal cord injuries[154]. - VAC2 is in a Phase 1 clinical trial funded by Cancer Research UK, targeting non-small cell lung cancer[154]. Financial Performance - Total revenues for the three months ended June 30, 2021, increased by $126,000 (33%) to $512,000 compared to $386,000 in the same period of 2020[176]. - Collaboration revenues rose by $213,000 (100%) for the three months ended June 30, 2021, primarily due to the ITI collaborative agreement[176]. - Royalties from product sales and license fees increased by $129,000 (130%) for the three months ended June 30, 2021, compared to the prior year[176]. - Grant revenues decreased by $216,000 (75%) for the three months ended June 30, 2021, due to reduced grant-related activities[176]. - Total other income for the three months ended June 30, 2021, was $2,115,000, compared to a net expense of $128,000 in the same period of 2020[192]. - The company recorded a net unrealized gain on marketable equity securities of $590,000 for the three months ended June 30, 2021, compared to an unrealized loss of $4,146,000 in the same period of 2020[194]. - For the six months ended June 30, 2021, Lineage recorded a net cash used in operating activities of $12.8 million, reflecting a loss from operations of $14.1 million[214]. - Lineage had an accumulated deficit of $300.3 million as of June 30, 2021[210]. Expenses - Research and development expenses for the three months ended June 30, 2021, were $2,931,000, an increase of $126,000 (4%) from $2,805,000 in the same period of 2020[182]. - General and administrative expenses for the three months ended June 30, 2021, increased by $628,000 (16%) to $4,536,000 compared to $3,908,000 in the same period of 2020[182]. Cash and Liquidity - As of June 30, 2021, Lineage had $68.7 million in cash, cash equivalents, and marketable equity securities, providing sufficient liquidity for planned operations for at least twelve months[210]. - Cash provided by investing activities for the six months ended June 30, 2021, was $10.0 million, primarily from sales of OncoCyte holdings[216]. - Cash provided by financing activities for the six months ended June 30, 2021, was $32.3 million, mainly from the sale of common shares[218]. Accounting and Revenue Recognition - The company recognizes revenue based on the transfer of control of products or services, following a five-step approach as per ASC 606[165]. - Revenue from government grants is recognized when related costs are incurred, as government entities do not meet the definition of a "customer" under ASC 606[166]. - Lineage assesses going concern uncertainty to ensure sufficient cash and working capital for at least one year from the issuance date of financial statements[164]. - The company has not reported significant changes to its critical accounting policies since its last annual report[157]. - Lineage's financial statements are prepared in accordance with generally accepted accounting principles in the United States, requiring management to make estimates and assumptions[156]. Taxation - Lineage recognized a deferred tax benefit of $169,000 for the six months ended June 30, 2021, primarily related to federal net operating losses[206]. - The deferred tax liability recorded in connection with the Asterias Merger amounted to $10.8 million, related to fair value adjustments for acquired assets[203]. - The company expects that deferred income tax expense or benefit will vary based on changes in the closing stock prices of OncoCyte shares[208]. - Lineage established a full valuation allowance for deferred tax assets as of December 31, 2018, due to uncertainty in realizing future tax benefits[205]. Market Impact - The COVID-19 pandemic has impacted patient enrollment in clinical trials, potentially causing delays in ongoing studies[211]. - The company expects fluctuations in other income and expenses to continue based on changes in the market price of OncoCyte shares, impacting net income or loss reported[197].